The Economic Impact of Clinical Pharmacist Involvement in the Public Procurement for Medicines and in the Drug and Therapeutics Committee

The Economic Impact of Clinical Pharmacist Involvement in the Public Procurement for Medicines and in the Work of the Drug and Therapeutics Committee, Single-centre, Cost-minimisation Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04314336

Enrollment

10000

Registered

2020-03-19

Start date

2019-08-01

Completion date

2020-06-01

Last updated

2020-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rationalization

Keywords

Rationalization, Clinical Pharmacist, Public Procurement for Medicines, Drug and Therapeutics Committee

Brief summary

The investigators have performed cost-minimisation analysis and compared the expenses based on the plan for public procurement (without clinical pharmacist involvement) for drugs with the results of public procurement based on the revised plan for public procurement by the clinical pharmacist. The plan for public procurements was based on the 1 year quantity for each medicine used by the hospital in the previous year, based on the latest deliverable prices at the time of extracting the data to workbook for MS Excel program (ver. 2002, Microsoft, Redmond, WA, USA). The investigators have performed cost-minimisation analysis and compared the expenses for all received requests for medicines to the drug and therapeutics committee (DTC) for a decision in the 1 year period, before and after involvement of clinical pharmacist in the committee work. The expenses were based on approval decisions in the 1 year period for approval time period. The denial decisions were also calculated and reported. The denial period calculated in rationalisation of expenses were based on 1 year treatment period.

Interventions

DRUGPublic procurement

Cost minimisation study through public procurement

DRUGDrug and Therapeutics Committee

Cost minimisation analysis of results of the drug and therapeutics committee before and after clinical pharmacist involvement

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to 100 Years

Healthy volunteers

Inclusion criteria

* All patients in the hospital (inhospital patients)

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Reducing prices of medicines	1 year	Reduce prices of medicines in percentage, since different countries and hospitals have various budgets and medicine prices

Secondary

Measure	Time frame	Description
Rationalization of expenses	1 year	Rationalization of expenses through rquests for medicines sent to Drug and Therapeutics Committee

Countries

Croatia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026